Swainson J

Department of Psychiatry, University of Alberta, Edmonton, AB, Canada. Jennifer.swainson@ualberta.ca.

19 papers · ORCID

ArticleKetamine

A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.

Swainson J, Grewal P, Polard S +9

Europe PMC2026
ArticleMDMA

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Smith SA, Mohammad H, Lee LHN +13

Europe PMC2026
ArticleKetamine

Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis.

Lunsky I, Gutierrez G, Wang X +8

Europe PMC2026
ArticleKetamine

Are the current safety measures for the treatment of depression with esketamine sufficient?

Valentino K, Teopiz KM, Dri CE +3

Europe PMC2026
ArticleKetamine

A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program.

Stefanuk I, Chivers-Wilson K, Jetly R +4

Europe PMC2026
ArticleKetamine

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.

Swainson J, Brietzke E, Khullar A +2

Europe PMC2026
ArticleMDMA

Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review.

Janssen-Aguilar R, Meshkat S, Al-Shamali HF +14

Europe PMC2025
ArticlePsychedelics

Evolving Psychotherapeutic Approaches for PTSD: Beyond the Fear-Based Model.

Burback L, Winkler O, Jetly R +4

Europe PMC2025
ArticleKetamine

Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee.

Gutierrez G, Vazquez G, Ravindran N +8

Europe PMC2025
ArticleKetamine

Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications.

Teopiz KM, Lo HKY, Lakhani M +11

Europe PMC2025
ArticlePsilocybin

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.

Meshkat S, Malik G, Zeifman RJ +12

Europe PMC2025
ArticleKetamine

Ketamine and Perinatal Mental Health: Problems and Potentials.

Swainson J

Europe PMC2025
ArticleKetamine

Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects.

Stuart M, Stefanuk I, Comeau R +2

Europe PMC2025
ArticlePsilocybin

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.

Kurkova V, Winkler O, Greenshaw A +6

Europe PMC2025
ArticlePsilocybin

Psychedelics and Suicide-Related Outcomes: A Systematic Review.

Meshkat S, Malik T, Zeifman R +13

Europe PMC2025
ArticleKetamine

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Gutierrez G, Swainson J, Ravindran N +10

Europe PMC2024
ArticleKetamine

Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada.

Chrenek C, Duong B, Khullar A +3

Europe PMC2023
ArticleKetamine

A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential.

Chubbs B, Wang J, Archer S +4

Europe PMC2022
ArticleKetamine

Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.

Swainson J, Klassen LJ, Brennan S +4

Europe PMC2022